Skip to main content
Journal cover image

Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial

Publication ,  Journal Article
Richmond, P; Hatchuel, L; Dong, M; Ma, B; Hu, B; Smolenov, I; Li, P; Liang, P; Han, HH; Liang, J; Clemens, R
Published in: The Lancet
February 2021

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

The Lancet

DOI

ISSN

0140-6736

Publication Date

February 2021

Volume

397

Issue

10275

Start / End Page

682 / 694

Publisher

Elsevier BV

Related Subject Headings

  • General & Internal Medicine
  • 42 Health sciences
  • 32 Biomedical and clinical sciences
  • 11 Medical and Health Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Richmond, P., Hatchuel, L., Dong, M., Ma, B., Hu, B., Smolenov, I., … Clemens, R. (2021). Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. The Lancet, 397(10275), 682–694. https://doi.org/10.1016/s0140-6736(21)00241-5
Richmond, Peter, Lara Hatchuel, Min Dong, Brenda Ma, Branda Hu, Igor Smolenov, Ping Li, et al. “Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.” The Lancet 397, no. 10275 (February 2021): 682–94. https://doi.org/10.1016/s0140-6736(21)00241-5.
Richmond, Peter, et al. “Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.” The Lancet, vol. 397, no. 10275, Elsevier BV, Feb. 2021, pp. 682–94. Crossref, doi:10.1016/s0140-6736(21)00241-5.
Richmond P, Hatchuel L, Dong M, Ma B, Hu B, Smolenov I, Li P, Liang P, Han HH, Liang J, Clemens R. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. The Lancet. Elsevier BV; 2021 Feb;397(10275):682–694.
Journal cover image

Published In

The Lancet

DOI

ISSN

0140-6736

Publication Date

February 2021

Volume

397

Issue

10275

Start / End Page

682 / 694

Publisher

Elsevier BV

Related Subject Headings

  • General & Internal Medicine
  • 42 Health sciences
  • 32 Biomedical and clinical sciences
  • 11 Medical and Health Sciences